Bunova S S, Zamakhina O V, Usacheva E V, Nelidova A V, Voronina E N
Omsk State Medical University, Omsk, Russia.
Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russia.
Kardiologiia. 2017 Mar;57(3):20-24.
To assess effectiveness of a -blocker bisoprolol basing on a study of variability of cardiac rhythm and polymorphism of -1 adrenergic receptor gene (ADRB1).
We examined 99 patients with coronary atherosclerosis either with stable angina without history of vascular events or more than 6 month after myocardial infarction and/or coronary intervention.
Patients with coronary atherosclerosis including those after myocardial infarction had signs of autonomic dysfunction regardless of the presence of genetic polymorphism Gly389Arg ADRB1. Sympathetic influences at orthostatic test performed during taking bisoprolol were more pronounced in patients with Gly389Gly ADRB1 genotype than in patients with Gly389Arg ADRB1 genotype. Basing on this observation we conclude that the control by bisoprolol of heart rate regulation in patients with Gly389Gly ADRB1 genotype should be considered inadequate.
基于对心律变异性和β1肾上腺素能受体基因（ADRB1）多态性的研究，评估β受体阻滞剂比索洛尔的有效性。
我们检查了99例冠状动脉粥样硬化患者，这些患者要么患有稳定型心绞痛且无血管事件病史，要么在心肌梗死和/或冠状动脉介入治疗后超过6个月。
冠状动脉粥样硬化患者，包括心肌梗死后的患者，无论是否存在ADRB1基因多态性Gly389Arg，均有自主神经功能障碍的体征。服用比索洛尔期间进行直立试验时，Gly389Gly ADRB1基因型患者的交感神经影响比Gly389Arg ADRB1基因型患者更明显。基于这一观察结果，我们得出结论，对于Gly389Gly ADRB1基因型患者，比索洛尔对心率调节的控制应被认为是不足的。
